TherageniX

TherageniX is a company that develops bone graft-enhancing dry powder gene therapies. TherageniX's technology utilizes a proprietary non-viral delivery system to distribute target regenerative factor genes (e.g., VEGF for angiogenesis and BMP for osteogenesis) along with autologous bone marrow cells from the patient.